Our results demonstrated that astragalin treatment effectively hindered the TNF-α-induced phosphorylation of MAPK in RA-FLSs, including p38 and JNK, but not ERK, in a dose-dependent manner. This evidence concerns the gene TNF and rheumatoid arthritis.